Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Association of neuron-specific enolase values with outcomes in cardiac arrest survivors is dependent on the time of sample collection

D. Vondrakova, A. Kruger, M. Janotka, F. Malek, V. Dudkova, P. Neuzil, P. Ostadal,

. 2017 ; 21 (1) : 172. [pub] 20170708

Language English Country England, Great Britain

Document type Journal Article

BACKGROUND: Despite marked advances in intensive cardiology care, current options for outcome prediction in cardiac arrest survivors remain significantly limited. The aim of our study was, therefore, to compare the day-specific association of neuron-specific enolase (NSE) with outcomes in out-of-hospital cardiac arrest (OHCA) survivors treated with hypothermia. METHODS: Eligible patients were OHCA survivors treated with targeted temperature management at 33 °C for 24 h using an endovascular device. Blood samples for NSE levels measurement were drawn on days 1, 2, 3, and 4 after hospital admission. Thirty-day neurological outcomes according to the Cerebral Performance Category (CPC) scale and 12-month mortality were evaluated as clinical end points. RESULTS: A total of 153 cardiac arrest survivors (mean age 64.2 years) were enrolled in the present study. Using ROC analysis, optimal cutoff values of NSE for prediction of CPC 3-5 score on specific days were determined as: day 1 > 20.4 mcg/L (sensitivity 63.3%; specificity 82.1%; P = 0.002); day 2 > 29.0 mcg/L (72.5%; 94.4%; P < 0.001); and day 3 > 20.7 mcg/L (94.4%; 86.7%; P < 0.001). The highest predictive value, however, was observed on day 4 > 19.4 mcg/L (93.5%; 91.0%; P < 0.001); NSE value >50.2 mcg/L at day 4 was associated with poor outcome with 100% specificity and 42% sensitivity. Moreover, NSE levels measured on all individual days also predicted 12-month mortality (P < 0.001); the highest predictive value for death was observed on day 3 > 18.1 mcg/L (85.3%; 72.0%; P < 0.001). Significant association with prognosis was found also for changes in NSE at different time points. An NSE level on day 4 > 20.0 mcg/L, together with a change > 0.0 mcg/L from day 3 to day 4, predicted poor outcome (CPC 3-5) with 100% specificity and 73% sensitivity. CONCLUSIONS: Our results suggest that NSE levels are a useful tool for predicting 30-day neurological outcome and long-term mortality in OHCA survivors treated with targeted temperature management at 33 °C. The highest associations of NSE with outcomes were observed on day 4 and day 3 after cardiac arrest.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033839
003      
CZ-PrNML
005      
20240918120719.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13054-017-1766-2 $2 doi
035    __
$a (PubMed)28687073
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vondráková, Dagmar $u Cardiovascular Center, Na Homolce Hospital, Roentgenova 2, 15000, Prague, Czech Republic. dagmar.vondrakova@seznam.cz. $7 xx0322733
245    10
$a Association of neuron-specific enolase values with outcomes in cardiac arrest survivors is dependent on the time of sample collection / $c D. Vondrakova, A. Kruger, M. Janotka, F. Malek, V. Dudkova, P. Neuzil, P. Ostadal,
520    9_
$a BACKGROUND: Despite marked advances in intensive cardiology care, current options for outcome prediction in cardiac arrest survivors remain significantly limited. The aim of our study was, therefore, to compare the day-specific association of neuron-specific enolase (NSE) with outcomes in out-of-hospital cardiac arrest (OHCA) survivors treated with hypothermia. METHODS: Eligible patients were OHCA survivors treated with targeted temperature management at 33 °C for 24 h using an endovascular device. Blood samples for NSE levels measurement were drawn on days 1, 2, 3, and 4 after hospital admission. Thirty-day neurological outcomes according to the Cerebral Performance Category (CPC) scale and 12-month mortality were evaluated as clinical end points. RESULTS: A total of 153 cardiac arrest survivors (mean age 64.2 years) were enrolled in the present study. Using ROC analysis, optimal cutoff values of NSE for prediction of CPC 3-5 score on specific days were determined as: day 1 > 20.4 mcg/L (sensitivity 63.3%; specificity 82.1%; P = 0.002); day 2 > 29.0 mcg/L (72.5%; 94.4%; P < 0.001); and day 3 > 20.7 mcg/L (94.4%; 86.7%; P < 0.001). The highest predictive value, however, was observed on day 4 > 19.4 mcg/L (93.5%; 91.0%; P < 0.001); NSE value >50.2 mcg/L at day 4 was associated with poor outcome with 100% specificity and 42% sensitivity. Moreover, NSE levels measured on all individual days also predicted 12-month mortality (P < 0.001); the highest predictive value for death was observed on day 3 > 18.1 mcg/L (85.3%; 72.0%; P < 0.001). Significant association with prognosis was found also for changes in NSE at different time points. An NSE level on day 4 > 20.0 mcg/L, together with a change > 0.0 mcg/L from day 3 to day 4, predicted poor outcome (CPC 3-5) with 100% specificity and 73% sensitivity. CONCLUSIONS: Our results suggest that NSE levels are a useful tool for predicting 30-day neurological outcome and long-term mortality in OHCA survivors treated with targeted temperature management at 33 °C. The highest associations of NSE with outcomes were observed on day 4 and day 3 after cardiac arrest.
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x analýza $x krev $7 D015415
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a jednotky intenzivní péče $x organizace a řízení $x statistika a číselné údaje $7 D007362
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a modely neurologické $7 D008959
650    _2
$a neurologické vyšetření $x metody $7 D009460
650    _2
$a zástava srdce mimo nemocnici $x mortalita $7 D058687
650    _2
$a fosfopyruváthydratasa $x analýza $x krev $7 D010751
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a ROC křivka $7 D012372
650    _2
$a hodnocení rizik $x metody $7 D018570
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kruger, Andreas $u Cardiovascular Center, Na Homolce Hospital, Roentgenova 2, 15000, Prague, Czech Republic.
700    1_
$a Janotka, Marek $u Cardiovascular Center, Na Homolce Hospital, Roentgenova 2, 15000, Prague, Czech Republic.
700    1_
$a Malek, Filip $u Cardiovascular Center, Na Homolce Hospital, Roentgenova 2, 15000, Prague, Czech Republic.
700    1_
$a Dudkova, Vlasta $u Cardiovascular Center, Na Homolce Hospital, Roentgenova 2, 15000, Prague, Czech Republic.
700    1_
$a Neuzil, Petr $u Cardiovascular Center, Na Homolce Hospital, Roentgenova 2, 15000, Prague, Czech Republic.
700    1_
$a Ostadal, Petr $u Cardiovascular Center, Na Homolce Hospital, Roentgenova 2, 15000, Prague, Czech Republic.
773    0_
$w MED00006603 $t Critical care $x 1466-609X $g Roč. 21, č. 1 (2017), s. 172
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28687073 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20240918120715 $b ABA008
999    __
$a ok $b bmc $g 1340318 $s 1030833
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 21 $c 1 $d 172 $e 20170708 $i 1466-609X $m Critical care $n Crit Care $x MED00006603
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Logged in users only

Archiving options

Loading data ...